Life Sciences & Health Care

Pipeline strategy: Measuring the return from pharmaceutical innovation

Return on investment in biopharmaceutical R&D has increased for the second consecutive year, to 5.9%, driven by a surge in high-value products entering the late-stage pipeline. However, this progress appears fragile as rising R&D costs continue to pose a challenge to sustainable R&D. Participants will demonstrate a greater understanding of pipeline investment and portfolio strategies and factors that appear to be driving improvements in the ROI.

2025 life sciences and health care outlook: Navigating key trends and challenges
January 29, 2025

Email Dbriefs
Subscribe to Dbriefs
Dbriefs Calendar
CPE information
Recent On-demand webcasts
Webcast help
Dbriefs FAQs
Dbriefs mobile viewing FAQs
Update profile, interests and subscriptions
Dbriefs series
Dbriefs homepage